For example, patients with high-risk disease (stage 4) are older than 18 months (median presentation age) and present metastases; their cancers show MYCN amplification, 1p deletion, 17q gain, 11q LOH, diploidy, as well as high LDH and ferritin levels—otherwise they are grouped to non-high-risk disease (stage 1–3) [5]. The gene discussed is MYCN; the disease is cancer.